Robert Hood
Endocrinology, Diabetes & Metabolism · Beaumont, TXNPI 1053321539
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $955,575 of the $1,296,780 with a category attached, or 73.7%. 47 manufacturers reported payments, led by Amgen at 39.4% of the total. Reporting peaked in 2019 at $364,764 and has fallen 61.6% since, to $140,108 in 2025. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,484 payments — averaging $522.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$511K
- Lilly USA, LLC$503K
- Novo Nordisk$228K
- Boehringer Ingelheim$27K
- Johnson & Johnson$12K
- Medtronic$5K
- plus $12K from 41 others
Across 100 payments — averaging $1840.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$173K
- Novo Nordisk AS$7K
- Eli Lilly$4K
What the payments were for
- Consulting fees$34,1113%
- Speaking & faculty fees$955,57574%
- Travel & lodging$268,98421%
- Food & beverage$38,0543%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$275,976
- Prolia$223,176
- MOUNJARO$184,352
- Ozempic$161,504
- TRULICITY$119,642
- JARDIANCE$67,691
- HUMULIN$63,342
- RYBELSUS$42,782
- Tresiba$12,644
- INVOKANA$11,191
- MINIMED 780G$2,389
- t-slim insulin pump$1,700
- t:slim X2 insulin pump$900
How this compares
$1,296,780 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 215 | $320,072 |
| MounjaroTirzepatide | 150 | $247,745 |
| JardianceEmpagliflozin | 140 | $139,056 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $93,747 |
| TrulicityDulaglutide | 46 | $85,905 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $36,255 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $34,736 |
| TradjentaLinagliptin | 35 | $33,632 |
| SynthroidLevothyroxine Sodium | 353 | $30,545 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $25,662 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $23,308 |
| Repatha SureclickEvolocumab | 24 | $22,530 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $22,136 |
| JanuviaSitagliptin Phosphate | 17 | $22,047 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $18,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp | $227,569 | $345,734230 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $503,274 | $341,000235 claims |
| Boehringer IngelheimJardiance, Tradjenta | $26,879 | $172,687175 claims |
| AbbVieSynthroid | $630 | $30,545353 claims |
| MerckJanuvia | $118 | $22,04717 claims |
| AstraZenecaFarxiga | $204 | $17,21518 claims |
| Amneal Pharmaceuticals LLCUnithroid | $343 | $3,92075 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Beaumont
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
- Mitchell SorsbyPlano$945K
- Andres SplenserHouston$923K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.